Active, not recruitingPhase 2NCT04430699

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Studying Vulvar carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Oladapo Yeku, MD, PHD
Massachusetts General Hospital
Intervention
Cisplatin(drug)
Enrollment
24 enrolled
Eligibility
18 years · FEMALE
Timeline
2020 – 2028

Study locations (2)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04430699 on ClinicalTrials.gov

Other trials for Vulvar carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Vulvar carcinoma →

← Back to all trials